Last reviewed · How we verify
DT3aP-HBs-IPV
DT3aP-HBs-IPV is a combination vaccine that provides immunization against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis through simultaneous administration of multiple antigens.
DT3aP-HBs-IPV is a combination vaccine that provides immunization against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis through simultaneous administration of multiple antigens. Used for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis in infants and children.
At a glance
| Generic name | DT3aP-HBs-IPV |
|---|---|
| Also known as | Infanrix® hexa |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This pentavalent vaccine works by introducing inactivated or toxoid forms of five pathogens to stimulate both humoral and cellular immune responses. The diphtheria and tetanus components use toxoids (inactivated toxins), the acellular pertussis component uses purified bacterial antigens, the hepatitis B component uses recombinant surface antigen, and the inactivated polio vaccine provides protection against all three poliovirus serotypes. Together, these antigens prime the immune system to recognize and neutralize these pathogens upon natural exposure.
Approved indications
- Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DT3aP-HBs-IPV CI brief — competitive landscape report
- DT3aP-HBs-IPV updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI